ダウンロード数: 498

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
64_10_397.pdf938.9 kBAdobe PDF見る/開く
タイトル: 腎細胞癌に対しNivolumab投与中に関節リウマチを発症した1例
その他のタイトル: A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma
著者: 富澤, 満  KAKEN_name
中井, 靖  KAKEN_name
前阪, 郁賢  KAKEN_name
尾張, 拓也  KAKEN_name
原, 良太  KAKEN_name
三宅, 牧人  KAKEN_name
井上, 剛志  KAKEN_name
穴井, 智  KAKEN_name
田中, 宣道  KAKEN_name
藤本, 清秀  KAKEN_name
著者名の別形: Tomizawa, Mitsuru
Nakai, Yasushi
Maesaka, Fumisato
Owari, Takuya
Hara, Ryota
Miyake, Makito
Inoue, Takeshi
Anai, Satoshi
Tanaka, Nobumichi
Fujimoto, Kiyohide
キーワード: Nivolumab
Rheumatoid arthritis
Renal cell carcinoma
Immune-related adverse events
発行日: 31-Oct-2018
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 64
号: 10
開始ページ: 397
終了ページ: 401
抄録: A 66-year-old man underwent nephrectomy for right renal cell carcinoma (cT3bNOMl (PUL)). Thereafter, he was treated with sunitinib for lung metastasis as the first-line therapy for 5 months and then axitinib as the second-line therapy for 2 months. Because lung metastasis progressed despite molecular targeted therapies, nivolumab was used as the third-line treatment. Three months later, he complained of painful stiffness in hands and wrist joints symmetrically. He was diagnosed as having rheumatoid arthritis. Treatment with nivolumab was discontinued and prednisolone and methotrexate were started. Although the painful stiffness in joints was improved l month later, synovitis remained partially 6 months after starting treatment of disease with anti-rheumatic drugs. Therefore, treatment for rheumatoid arthritis was continued. On the other hand, because the lung lesion had progressed 2 months after discontining nivolumab, everolimus was used as the fourth-line therapy.
著作権等: 許諾条件により本文は2019/11/01に公開
DOI: 10.14989/ActaUrolJap_64_10_397
URI: http://hdl.handle.net/2433/235683
PubMed ID: 30543737
出現コレクション:Vol.64 No.10

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。